*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Jada Selma
BME PhD Proposal
Date: August 3, 2017
Time: 12:00 pm
Location: Suddath Seminar room (IBB 1128)
Advisor: Edward A. Botchwey, PhD
Thesis committee: Manu O. Platt, PhD
Wilbur Lam, MD, PhD
Fredrik Vannberg, PhD
Luke Mortensen, PhD
Title: The Role of Sphingolipid Metabolism in Bone Stem Cells and Sickle Bone Disease
Abstract: Sickle cell disease (SCD) is the most common inherited blood disorder in the U.S. SCD affects approximately 100,000 people domestically and an additional 300,000 babies born globally every year. A collection of pathologies, including osteonecrosis (ON), osteoporosis (OP), and osteopenia, known as sickle bone disease (SBD) are among the most common complications of SCD, which progresses from adolescence and occurs in 50% of individuals by age 35. Transgenic sickle mouse model studies have shown that increased osteoclast activity and reduced mesenchymal stem cell (MSC) differentiation into osteoblasts contributes broadly to pathological bone remodeling in SCD, but underlying cellular and molecular mechanisms are poorly understood. Sphingosine 1-phosphate (S1P), a type of sphingolipid (SL), directs a wide array of cellular processes including, migration, cell-cell adhesion, survival, and proliferation. S1P has also been found to direct MSCs towards an osteogenic lineage and modulates their migration. Moreover, we previously showed that dysregulated sphingolipid (SL) metabolism in SCD increased production and release of cell-derived microvesicles (SS MVs), which in turn induced pro-inflammatory cytokine secretion, dysregulation of mitogen activated protein kinase (MAPK) signatures, and elevated proteolytic activity of cathepsins (cat) S and K. The overall hypothesis of this proposed research is that dysregulated sphingolipid metabolism and signaling within MSCs reduces osteogenic potential and contributes to sickle bone disease. First, we will determine if differences in sphingolipid levels between normal and sickle MSCs contribute to sickle MSCs’ decreased ability to differentiate into osteoblasts. Second, we will utilize endogenous MSC mobilization to enhance allogenic MSC survival and engraftment and subsequent bone regeneration in a SCD murine model. This work will elucidate potential therapeutic targets for ON treatment in SCD as well as improve MSC therapy for other bone disorders.
